Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan Maintenance Treatment in Advanced Ovarian Cancer
NCT07318558Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2026
- Primary completion
- Feb 2033
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 30
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in ovarian cancer, sponsored by Merck & Co.. Started Feb 2026; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07318558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07318558.